Current Edition

announces

NANOBIOTIX ANNOUNCES POSITIVE PHASE II/III TOPLINE DATA IN SOFT TISSUE SARCOMA WITH NBTXR3

Trial achieved its primary endpoint of pathological Complete Response Rate Trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrated significant superiority and clinical …

Continue Reading →